Abstract
Background: The current study was performed to determine the effects of cumin cyminum L. intake on weight loss and metabolic profiles among overweight subjects. Methods: This randomized double-blind placebo-controlled clinical trial was conducted among 78 overweight subjects (male, n = 18; female, n = 60) aged 18-60 years old. Participants were randomly assigned into three groups to receive: (1) cumin cyminum L. capsule (n = 26); (2) orlistat120 capsule (n = 26) and (3) placebo (n = 26) three times a day for 8 weeks. Anthropometric measures and fasting blood samples were taken at baseline and after 8 weeks of intervention. Results: Consumption of the Cuminum cyminum L. and orlistat120 resulted in a similar significant decrease in weight (-1.1 ± 1.2 and -0.9 ± 1.5 vs. 0.2 ± 1.5 kg, respectively, p = 0.002) and BMI (-0.4 ± 0.5 and -0.4 ± 0.6 vs. 0.1 ± 0.6 kg/m2, respectively, p = 0.003) compared with placebo. In addition, taking Cuminum cyminum L., compared with orlistat and placebo, led to a significant reduction in serum insulin levels (-1.4 ± 4.5 vs. 1.3 ± 3.3 and 0.3 ± 2.2 µIU/ml, respectively, p = 0.02), HOMA-B (-5.4 ± 18.9 vs. 5.8 ± 13.3 and 1.0 ± 11.0, respectively, p = 0.02) and a significant rise in QUICKI (0.01 ± 0.01 vs. -0.005 ± 0.01 and -0.004 ± 0.01, respectively, p = 0.02). Conclusion: Taking cumin cyminum L. for eight weeks among overweight subjects had the same effects of orlistat120 on weight and BMI and beneficial effects on insulin metabolism compared with orlistat120 and placebo.
Journal Section:
Original Paper
References
1.
Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - the evidence report. National institutes of health. Obes Res 1998;6(suppl 2):51S-209S.
[PubMed]
2.
Shah R, Gayat E, Januzzi JL Jr, Sato N, Cohen-Solal A, diSomma S, Fairman E, Harjola VP, Ishihara S, Lassus J, Maggioni A, Metra M, Mueller C, Mueller T, Parenica J, Pascual-Figal D, Peacock WF, Spinar J, van Kimmenade R, Mebazaa A: Body mass index and mortality in acutely decompensated heart failure across the world: a global obesity paradox. J Am Coll Cardiol 2014;63:778-785.
[PubMed]
3.
Mirzazadeh A, Salimzadeh H, Arabi M, Navadeh S, Hajarizadeh B, Haghdoost AA: Trends of obesity in Iranian adults from 1990s to late 2000s; a systematic review and meta-analysis. Middle East J Dig Dis 2013;5:151-157.
[PubMed]
4.
Lau DC, Douketis JD, Morrison KM, Hramiak IM, Sharma AM, Ur E: 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]. CMAJ 2007;176:S1-S13.
[PubMed]
5.
Catenacci VA, Hill JO, Wyatt HR: The obesity epidemic. Clin Chest Med 2009;30:415-444.
[PubMed]
6.
Yanovski SZ, Yanovski JA: Long-term drug treatment for obesity: a systematic and clinical review. JAMA 2014;311:74-86.
[PubMed]
7.
Colquitt JL, Picot J, Loveman E, Clegg AJ: Surgery for obesity. Cochrane Database Syst Rev 2009;2:CD003641.
[PubMed]
8.
Haslam DW, James WP: Obesity. Lancet 2005;366:1197-1209.
[PubMed]
9.
Kan Y, Kartal M, Ozek T, Aslan S, Baser K: Composition of essential oil of Cuminum cyminum L. according to harvesting times. Turkish J Pharm Sci 2007;1:25-29.
10.
Dhandapani S, Subramanian VR, Rajagopal S, Namasivayam N: Hypolipidemic effect of Cuminum cyminum L. on alloxan-induced diabetic rats. Pharmacol Res 2002;46:251-255.
[PubMed]
11.
Ahmad M, Akhtar MS, Malik T, Gilani AH: Hypoglycaemic action of the flavonoid fraction of Cuminum nigrum seeds. Phytother Res 2000;14:103-106.
[PubMed]
12.
Mae T, Kishida H, Nishiyama T, Tsukagawa M, Konishi E, Kuroda M, Mimaki Y, Sashida Y, Takahashi K, Kawada T, Nakagawa K, Kitahara M: A licorice ethanolic extract with peroxisome proliferator-activated receptor-gamma ligand-binding activity affects diabetes in KK-Ay mice, abdominal obesity in diet-induced obese C57BL mice and hypertension in spontaneously hypertensive rats. J Nutr 2003;133:3369-3377.
[PubMed]
13.
Datau EA, Wardhana, Surachmanto EE, Pandelaki K, Langi JA; Fias: Efficacy of Nigella sativa on serum free testosterone and metabolic disturbances in central obese male. Acta Med Indones 2010;42:130-134.
[PubMed]
14.
Benzie IF, Strain JJ: The ferric reducing ability of plasma (FRAP) as a measure of ‘antioxidant power': the FRAP assay. Anal Biochem 1996;239:70-76.
[PubMed]
15.
Beutler E, Gelbart T: Plasma glutathione in health and in patients with malignant disease. J Lab Clin Med 1985;105:581-584.
[PubMed]
16.
Pisprasert V, Ingram KH, Lopez-Davila MF, Munoz AJ, Garvey WT: Limitations in the use of indices using glucose and insulin levels to predict insulin sensitivity: impact of race and gender and superiority of the indices derived from oral glucose tolerance test in African Americans. Diabetes Care 2013;36:845-853.
[PubMed]
17.
Badary OA: Thymoquinone attenuates ifosfamide-induced Fanconi syndrome in rats and enhances its antitumor activity in mice. J Ethnopharmacol 1999;67:135-142.
[PubMed]
18.
Hamilton-Fairley D, Kiddy D, Anyaoku V, Koistinen R, Seppala M, Franks S: Response of sex hormone binding globulin and insulin-like growth factor binding protein-1 to an oral glucose tolerance test in obese women with polycystic ovary syndrome before and after calorie restriction. Clin Endocrinol (Oxf) 1993;39:363-367.
[PubMed]
19.
Kiddy DS, Hamilton-Fairley D, Seppala M, Koistinen R, James VH, Reed MJ, Franks S: Diet-induced changes in sex hormone binding globulin and free testosterone in women with normal or polycystic ovaries: correlation with serum insulin and insulin-like growth factor-I. Clin Endocrinol (Oxf) 1989;31:757-763.
[PubMed]
20.
Moran LJ, Noakes M, Clifton PM, Tomlinson L, Galletly C, Norman RJ: Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:812-819.
[PubMed]
21.
Sacks FM, Campos H: Polyunsaturated fatty acids, inflammation, and cardiovascular disease: time to widen our view of the mechanisms. J Clin Endocrinol Metab 2006;91:398-400.
[PubMed]
22.
Talpur N, Echard B, Ingram C, Bagchi D, Preuss H: Effects of a novel formulation of essential oils on glucose-insulin metabolism in diabetic and hypertensive rats: a pilot study. Diabetes Obes Metab 2005;7:193-199.
[PubMed]
23.
Badr G, Mahmoud MH, Farhat K, Waly H, Al-Abdin OZ, Rabah DM: Maternal supplementation of diabetic mice with thymoquinone protects their offspring from abnormal obesity and diabetes by modulating their lipid profile and free radical production and restoring lymphocyte proliferation via PI3K/AKT signaling. Lipids Health Dis 2013;12:37.
[PubMed]
24.
Frayn KN: Insulin resistance, impaired postprandial lipid metabolism and abdominal obesity. A deadly triad. Med Princ Pract 2002;11(suppl 2):31-40.
[PubMed]
25.
El-Dakhakhny M, Mady N, Lembert N, Ammon HP: The hypoglycemic effect of Nigella sativa oil is mediated by extrapancreatic actions. Planta Med 2002;68:465-466.
[PubMed]
26.
Samani KG, Farrokhi E: Effects of cumin extract on oxLDL, paraoxanase 1 activity, FBS, total cholesterol, triglycerides, HDL-C, LDL-C, Apo A1, and Apo B in in the patients with hypercholesterolemia. Int J Health Sci (Qassim) 2014;8:39-43.
[PubMed]
27.
Gupta RS, Saxena P, Gupta R, Kachhawa JB: Evaluation of reversible contraceptive activities of Cuminum cyminum in male albino rats. Contraception 2011;84:98-107.
[PubMed]
28.
Shirke SS, Jagtap AG: Effects of methanolic extract of Cuminum cyminum on total serum cholesterol in ovariectomized rats. Indian J Pharmacol 2009;41:92-93.
[PubMed]
29.
Amin KA, Nagy MA: Effect of Carnitine and herbal mixture extract on obesity induced by high fat diet in rats. Diabetol Metab Syndr 2009;1:17.
[PubMed]
© 2015 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2015
You do not currently have access to this content.
